Broad immunogenicity to prior SARS-CoV-2 strains and JN.1 variant elicited by XBB.1.5 vaccination in nursing home residents DOI Open Access
Yasin Abul,

Clare Nugent,

Igor Vishnepolskiy

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: March 24, 2024

SARS-CoV-2 vaccination has reduced hospitalization and mortality for nursing home residents (NHRs). However, emerging variants coupled with waning immunity, immunosenescence, variability of vaccine efficacy undermine effectiveness. We therefore need to update our understanding the immunogenicity most recent XBB.1.5 monovalent variant strains among NHRs. The current study focuses on a subset participants from longitudinal consented NHRs HCWs who have received serial blood draws assess each mRNA dose. report data after FDA approval in Fall 2023. were classified based whether they had an interval infection between their first bivalent dose vaccination. sample included 61 [median age 76 (IQR 68-86), 51% female] 28 45 31-58), 46% female). Following vaccination, there was robust geometric mean fold rise (GMFR) XBB.1.5-specific neutralizing antibody titers 17.3 (95% confidence [CI] 9.3, 32.4) 11.3 CI 5, 25.4) without infection, respectively. GMFR 13.6 8.4,22). Similarly, we noted JN.1-specific 14.9 7.9, 28) 6.5 3.3, 13.1) 11.4 6.2, 20.9) HCWs. higher across all analyzed following compared infection. significantly elevates Omicron-specific JN.1 both This response more pronounced individuals known be infected since All authors certify that this work entitled " Broad prior elicited by is novel. It shows healthcare workers XBB BA.28.6/JN.1 strains. important increased less than 0.1% 94% COVID-19 cases October 2023 February 2024 US. information timely given CDC's latest recommendation adults 65 older receive Spring booster. Since produces compelling prevalent circulating strain residents, findings add support rationale encourage uptake. Emerging together variable reduce effectiveness residents.XBB.1.5 antibodies workers, although absolute XBB.1.5Why does paper matter? Among strain, which represents U.S. as 2024.

Language: Английский

XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1 DOI Creative Commons
Qian Wang, Yicheng Guo, Anthony Bowen

et al.

Cell Host & Microbe, Journal Year: 2024, Volume and Issue: 32(3), P. 315 - 321.e3

Published: Feb. 19, 2024

COVID-19 vaccines have recently been updated to specifically encode or contain the spike protein of SARS-CoV-2 XBB.1.5 subvariant, but their immunogenicity in humans has yet be fully evaluated and reported, particularly against emergent viruses that are rapidly expanding. We now report administration an monovalent mRNA vaccine booster (XBB.1.5 MV) previously uninfected individuals boosted serum virus-neutralizing antibodies significantly not only (27.0-fold increase) EG.5.1 (27.6-fold also key emerging such as HV.1, HK.3, JD.1.1, JN.1 (13.3- 27.4-fold increase). Individuals infected by Omicron subvariant had highest overall neutralizing titers (ID

Language: Английский

Citations

111
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden DOI Open Access
Ulrika Marking, Oscar Bladh,

Katherina Aguilera

et al.

The Lancet Infectious Diseases, Journal Year: 2024, Volume and Issue: 24(2), P. e80 - e81

Published: Jan. 5, 2024

Language: Английский

Citations

25
Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1 DOI Creative Commons
Ninaad Lasrado, Annika Rössler, Marjorie Rowe

et al.

Vaccine, Journal Year: 2024, Volume and Issue: 42(9), P. 2117 - 2121

Published: March 7, 2024

A new highly mutated Omicron subvariant BA.2.87.1 has recently been identified with over 30 amino acid mutations in the Spike protein compared BA.2, BA.5, XBB.1.5, and JN.1 variants. Mutiple are located N-terminal domain (NTD) rather than receptor binding (RBD) of protein. We evaluated neutralizing antibody (NAb) responses to because its sequence unique NTD region. Our data show that NAb were lower BA.2 but higher JN.1, suggesting is not a further escape variant other currently circulating Moreover, XBB.1.5 mRNA boosting increased titers all variants tested including BA.2.87.1.

Language: Английский

Citations

16
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study DOI

Katia Alves,

Karen L. Kotloff,

R. Scott McClelland

et al.

The Lancet Infectious Diseases, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

2
Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies DOI

Qingwen He,

Yaling An,

Xuemei Zhou

et al.

Med, Journal Year: 2024, Volume and Issue: 5(5), P. 401 - 413.e4

Published: April 3, 2024

Language: Английский

Citations

13
SARS-CoV-2 XBB.1.5 mRNA booster vaccination elicits limited mucosal immunity DOI
Ninaad Lasrado, Marjorie Rowe, Katherine McMahan

et al.

Science Translational Medicine, Journal Year: 2024, Volume and Issue: 16(770)

Published: Oct. 23, 2024

Current COVID-19 vaccines provide robust protection against severe disease but minimal acquisition of infection. Intramuscularly administered induce serum neutralizing antibodies (NAbs), their ability to boost mucosal immune responses remains be determined. In this study, we show that the XBB.1.5 messenger RNA (mRNA) boosters result in increased neutralization multiple acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants humans, including dominant circulating variant JN.1. contrast, found mRNA booster did not augment NAbs or IgA responses, although SARS-CoV-2 XBB infection substantially antibody responses. These data demonstrate current enhance peripheral do robustly increase Our highlight a separation between and systems humans emphasize importance developing next-generation immunity protect virus infections.

Language: Английский

Citations

8
A recombinant protein vaccine induces protective immunity against SARS-CoV-2 JN.1 and XBB-lineage subvariants DOI Creative Commons
H. J. Yang, Weiqi Hong, Shi H

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2025, Volume and Issue: 10(1)

Published: Feb. 25, 2025

Abstract The emergence of XBB- and JN.1-lineages with remarkable immune evasion characteristics have led to rises in breakthrough infections within populations. In addition, the unfavorable impacts imprinting, stemming from continuous exposure antigens circulated viruses, been observed incline response against earlier lineages, thereby declining neutralization newly emerged Omicron subvariants. this, advancement next-generation vaccines COVID-19 targeting components new subvariants such as XBB-lineage is imperative. current study, a self-assembled trimeric recombinant protein (RBD XBB.1.5 -HR) was generated by concatenating sequences receptor binding domain (RBD) derived heptad-repeat 1 (HR1) HR2 spike S2 subunit. Adjuvanted-RBD -HR induced robust humoral cellular responses, characterized elevated JN.1-inculuded substantial population antigen-specific T memory cells. Protective immunity conferred RBD vaccine preserved post-immunization, evidenced germinal center B (GC B) follicular helper (Tfh) sustained potency, an increase cells (MBCs) long-lived plasma (LLPCs). showed favorable boosting effect when administered heterologously after three doses inactivated virus (IV) mRNA vaccines. Significantly, it provided protection live EG.5.1 viruses vivo. monovalent safety immunogenicity, neutralizing antibodies JN.1- individuals prior vaccinations. These findings highlight its clinical potential safeguarding circulating

Language: Английский

Citations

1
Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccination DOI
Christine Happle, Markus Hoffmann,

Amy Kempf

et al.

The Lancet Infectious Diseases, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 1, 2024

Language: Английский

Citations

8
Immune responses following BNT162b2 XBB.1.5 vaccination in patients on haemodialysis in Germany DOI Open Access
Anne Cossmann, Markus Hoffmann, Metodi V. Stankov

et al.

The Lancet Infectious Diseases, Journal Year: 2024, Volume and Issue: 24(3), P. e145 - e146

Published: Jan. 8, 2024

Language: Английский

Citations

6
Towards a Safer Future: Enhancing Vaccine Development to Combat Animal Coronaviruses DOI Creative Commons
Fusheng Si,

Ruisong Yu,

Shijuan Dong

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(3), P. 330 - 330

Published: March 19, 2024

Coronaviruses (CoVs) are a large class of positively stranded RNA viruses that pose significant threat to public health, livestock farming, and wild animals. These have the ability cross species barriers cause devastating epidemics. Animals considered be intermediate hosts for many coronaviruses, animal coronaviruses also potential cross-species transmission humans. Therefore, controlling epidemic is great importance human health. Vaccination programs proven effective in infections, offering cost-effective approach reducing morbidity mortality, so re-emergence lethal emphasizes urgent need development vaccines. In this regard, we explore progress coronavirus vaccine development, covering latest taxonomy main spillover events, diverse platforms, targets primary challenges facing We emphasize create “dual-effect” capable eliciting both cellular humoral immune responses. The goal highlight contributions veterinary scientists field interdisciplinary collaboration between medical communities. By promoting communication cooperation, can enhance novel super vaccines combat infections future.

Language: Английский

Citations

6